WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Headquarters

CN

CEO

Ge Li

Listed since

Dec 13, 2018

Employees

33,834